Research analysts set expectations for Axsome Therapeutics, Inc.’s earnings. in Q3 2024 (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Analysts at Zacks Research reduced their Q3 2024 earnings per share estimates for shares of Axsome Therapeutics in a research note issued to investors on Wednesday, August 14th. Zacks Research analyst R. Department now anticipates that the company will earn ($1.31) per share for the quarter, down from their prior estimate of ($1.21). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.65) per share. Zacks Research also issued estimates for Axsome Therapeutics Q4 2024 earnings at ($1.19) EPS, FY2024 earnings at ($4.83) EPS, Q1 2025 earnings at ($1.12) EPS, Q2 earnings at ($1.12) EPS 2025 at ($1,302) EPS at ($1,302) ) EPS, Q4 2025 Earnings at ($0.56) EPS, FY2025 Earnings at ($3.68) EPS, Q1 2026 Earnings at ($0.19) EPS and Q2 2026 earnings at $0.39 EPS.

Several other equities research analysts have also recently weighed in on the company. Robert W. Baird raised their price target on Axsome Therapeutics from $108.00 to $112.00 and gave the company an “outperform” rating in a report on Tuesday, May 7th. Bank of America upgraded Axsome Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $95.00 to $106.00 in a report on Tuesday, August 6th. HC Wainwright dropped their target price on Axsome Therapeutics from $190.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. StockNews.com lowered Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 14th. Finally, Needham & Company LLC restated a “buy” rating and set a $130.00 target price on shares of Axsome Therapeutics in a report on Monday, August 5th. One analyst has rated the stock with a sell rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Moderate Buy” and a consensus price target of $123.38, according to MarketBeat.com.

Get the latest stock report on AXSM

Axsome Therapeutics price performance

AXSM opened at $86.17 on Monday. The stock has a 50-day moving average price of $81.49 and a 200-day moving average price of $79.03. Axsome Therapeutics has a 12-month low of $55.02 and a 12-month high of $98.40. The company has a current ratio of 3.20, a quick ratio of 3.09, and a debt-to-equity ratio of 1.25. The stock has a market cap of $4.09 billion, a P/E ratio of -13.51 and a beta of 1.26.

Institutional inputs and outputs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXSM. Northwestern Mutual Wealth Management Co. purchased a new stake in Axsome Therapeutics in the second quarter valued at $27,000. EntryPoint Capital LLC purchased a new stake in Axsome Therapeutics in the 1st quarter valued at $35,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Axsome Therapeutics during the second quarter valued at $47,000. Russell Investments Group Ltd. raised its stake in Axsome Therapeutics by 5,550.0% in the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock valued at $63,000 after purchasing an additional 777 shares during the last quarter. Finally, Covestor Ltd raised its stake in Axsome Therapeutics by 54,750.0% in the 1st quarter. Covestor Ltd now owns 1,097 shares of the company’s stock valued at $88,000 after purchasing an additional 1,095 shares during the last quarter. Institutional investors own 81.49% of the company’s shares.

Insider Trading at Axsome Therapeutics

In other news, COO Mark L. Jacobson sold 7,910 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $74.31, for a total value of $587,792.10. Following the completion of the transaction, the chief operating officer now owns 5,783 shares of the company’s stock, valued at approximately $429,734.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed via this hyperlink. In other news, COO Mark L. Jacobson sold 7,910 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $74.31, for a total value of $587,792.10. Following the completion of the transaction, the chief operating officer now owns 5,783 shares of the company’s stock, valued at approximately $429,734.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed via this hyperlink. Also, Director Mark Coleman sold 5,249 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $75.21, for a total value of $394,777.29. Following the transaction, the director now directly owns 19,848 shares of the company’s stock, valued at approximately $1,492,768.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,898 shares of company stock worth $5,005,058. Corporate insiders own 22.40% of the company’s shares.

Axsome Therapeutics Company Profile

(Get a free report)

Axsome Therapeutics, Inc, a biopharmaceutical company, is engaged in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), an N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a drug indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

See Also

Get news and reviews for Axsome Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axsome Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.